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IL-1a and TNFa Down-Regulate CRH Receptor-2 mRNA
Expression in the Mouse Heart
SARAH C. COSTE,* KURT A. HELDWEIN,* SUSAN L. STEVENS,
ERIC TOBAR-DUPRES, AND MARY P. STENZEL-POORE
Department of Molecular Microbiology and Immunology, Oregon Health Sciences University, Portland,
Oregon 97201
Two receptors (CRH receptor type 1 and CRH receptor type 2)
have been identified for the stress-induced neuropeptide, CRH
and related peptides, urocortin, and urocortin II. We previously
found marked down-regulation of cardiac CRH receptor type 2
expression following administration of bacterial endotoxin, li-
popolysaccharide, a model of systemic immune activation, and
inflammation. We postulated that inflammatory cytokines may
regulate CRH receptor type 2. We show that systemic IL-1a ad-
ministration significantly down-regulates CRH receptor type 2
mRNA in mouse heart. In addition, TNFa treatment also reduces
CRH receptor type 2 mRNA expression, although the effect was
not as marked as with IL-1a. However, CRH receptor type 2
mRNA expression is not altered in adult mouse ventricular car-
diomyocytes stimulated in vitro with TNFa or IL-1a. Thus, cy-
tokine regulation may be indirect. Exogenous administration of
corticosterone in vivo or acute restraint stress also reduces car-
diac CRH receptor type 2 mRNA expression, but like cytokines,
in vitro corticosterone treatment does not modulate expression
in cardiomyocytes. Interestingly, treatment with urocortin sig-
nificantly decreases CRH receptor type 2 mRNA in cultured
cardiomyocytes. We speculate that in vivo, inflammatory medi-
ators such as lipopolysaccharide and/or cytokines may increase
urocortin, which in turn down-regulates CRH receptor type 2
expression in the heart. Because CRH and urocortin increase
cardiac contractility and coronary blood flow, impaired CRH
receptor type 2 function during systemic inflammation may ul-
timately diminish the adaptive cardiac response to adverse
conditions. (Endocrinology 142: 3537–3545, 2001)
CRH is well known as a primary mediator of the mam-malian stress response, acting through numerous
central pathways to initiate an array of neuroendocrine,
behavioral, and autonomic adaptive changes (1). Consid-
erable evidence also suggests a role for CRH in regulating
peripheral responses. Iv administration of CRH elicits a
number of cardiovascular changes that include marked
hypotension and vasodilation in selective vascular beds
(2– 4). Direct actions of CRH have been demonstrated in
isolated working heart preparations where addition of
CRH induces a sustained increase in coronary blood flow,
a transient positive inotropic effect, and a rapid rise in the
release of atrial natriuretic peptide (5). Urocortin (Ucn), a
member of the CRH family which shares 45% homology to
rat/human CRH and 63% homology to fish urotensin, also
has pronounced effects on the cardiovascular system when
given systemically that exceed those elicited by CRH (6).
Ucn produces a marked, long-lasting (.30 min) reduction
in mean arterial pressure in rats (6) and increases cardiac
contractility and coronary blood flow in sheep (7). It is
unknown as yet whether the recently discovered CRH-
related peptide, urocortin II (Ucn-II), significantly influ-
ences cardiovascular function (8).
CRH receptor type 2 (CRH-R2), which bears 69% se-
quence identity with CRH receptor type 1 (CRH-R1) (9 –
12), is highly expressed in peripheral sites, including heart,
skeletal muscle, gastrointestinal tract and arterioles, with
lower levels of expression in limited brain regions (11,
13–15). This pattern of expression is distinct from CRH-R1,
which is found predominantly in the pituitary and various
brain regions including cerebral cortex, cerebellum, and
brain stem (10, 16). We have recently shown that murine
cardiovascular responses to systemic Ucn depend criti-
cally on CRH-R2. Ucn causes a pronounced decrease in
mean arterial pressure in wild-type mice, whereas mice
lacking functional CRH-R2 (Crhr22/2) do not show this
hypotensive response to Ucn (17). In addition, we found
that Ucn injection increases the velocity of left ventricular
contraction in wild-type mice but again had no effect in
Crhr22/2 mice. Thus, Crhr22/2 mice do not display mea-
surable cardiovascular responses to systemic Ucn, pro-
viding strong evidence that CRH-R2 mediates Ucn-
induced effects on cardiovascular function. CRH-R2
located on cardiac myocytes may mediate CRH/Ucn ac-
tions on the myocardium in vivo since neonatal cardiac
myocytes express CRH-R2 and respond to CRH stimula-
tion in vitro with increases in intracellular cAMP (18).
Interestingly, CRH-R2 has approximately 40-fold greater
affinity for Ucn than for CRH (6). This unique sensitivity
to Ucn and the greater potency of Ucn in eliciting cardio-
vascular responses are in keeping with the proposal that
a peripheral regulatory system comprised of Ucn and
CRH-R2 may exist (6).
The role of a peripheral CRH/Ucn system that is stress-
responsive remains unclear. Previous studies from our lab-
oratory have shown that CRH-R2 mRNA levels in the heart
are markedly down-regulated (;9-fold) following adminis-
tration of bacterial endotoxin [lipopolysaccharide (LPS)] (19).
Furthermore, we found that LPS had the opposite effect on
CRH-R2 in skeletal muscle leading to increased (;3-fold)
Abbreviations: CRH-R1 or R2, CRH receptor type 1 or 2; HPA,
hypothalamic-pituitary-adrenal; iNOS, inducible nitric oxide synthase;
LPS, lipopolysaccharide; SON, supraoptic nucleus; Ucn, urocortin.
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CRH-R2 expression. Thus, endotoxin has differential effects
on CRH-R2 expression in the periphery—up-regulation in
skeletal muscle and down-regulation in the heart. Together,
these studies establish an important link between CRH-R2
and inflammation and suggest that a CRH/Ucn system in the
periphery may be activated during immune challenge, which
subsequently contributes to local cardiac and skeletal muscle
responses.
Endotoxemia and systemic inflammation is marked by
increased cytokine production by both immune and non-
immune cells in the periphery. Proinflammatory cyto-
kines, such as TNFa, IL-1, and IL-6, modulate CRH path-
ways in the central nervous system (20, 21), raising the
possibility that peripheral CRH pathways may be simi-
larly regulated by these immune mediators. Moreover,
these cytokines are known to have prominent effects on the
cardiovascular system. Systemic administration of TNFa
or IL-1, acting in part through nitric oxide pathways, in-
duces vasodilation and hypotension— effects that mimic
the cardiovascular sequelae of endotoxin exposure. Ac-
cordingly, neutralization of TNFa or antagonism of IL-1
receptors diminishes the lethal effects of endotoxin in
mammals (22–25). Direct effects of these cytokines have
been demonstrated wherein TNFa and IL-1 directly de-
press cardiomyocyte contractility in vitro (26). Thus, cy-
tokines could potentially modulate CRH pathways di-
rectly in peripheral tissues. Alternatively, stimulation of
CRH gene expression in the hypothalamic paraventricular
nucleus by endotoxin and/or cytokines (e.g. IL-1 and IL-6)
leads to activation of the hypothalamic-pituitary-adrenal
(HPA) axis and an elevation in circulating glucocorticoids
(20, 21). High levels of glucocorticoids have been shown
to down-regulate CRH-R1 in the hypothalamus and the
pituitary (27); thus it is conceivable that CRH-R2 in the
periphery may be negatively regulated by glucocorticoids
that increase during sepsis and inflammation.
To test whether cytokines regulate CRH-R2 expression in
the heart, we injected mice ip with the inflammatory cyto-
kines, TNFa and IL-1a. Here we report that recombinant
TNFa and IL-1a markedly down-regulate CRH-R2 in the
heart in vivo. However, we find that TNFa and IL-1a do not
regulate CRH-R2 mRNA in isolated mouse cardiomyocytes
in vitro, suggesting that the suppressive effects of these cy-
tokines, in vivo, occur indirectly. In testing alternative routes
of modulation, we find that both in vivo corticosterone treat-
ment or exposure to restraint stress reduces CRH-R2 mRNA
expression in the mouse heart. However, similar to cyto-
kines, in vitro treatment of corticosterone does not modulate
expression in cardiomyocytes. Interestingly, we find that the
high affinity CRH-R2 ligand, Ucn, significantly down-regu-
lates CRH-R2 in cardiomyocytes in vitro. Thus, we speculate
that endotoxin and/or cytokines increase CRH or Ucn ex-
pression in vivo, which, in turn down-regulates CRH-R2 ex-
pression in the heart.
Materials and Methods
Animals and reagents
C57Bl/6J mice were purchased from The Jackson Laboratory (Bar
Harbor, ME). TNFa receptor double knockout (p552/2, p752/2) mice
were obtained from Immunex Corp. (Seattle, WA). Mice were housed
under specific pathogen-free conditions on a 12-h light, 12-h dark sched-
ule and were given free access to pathogen-free laboratory chow and tap
water. All experimental procedures met NIH guidelines with the ap-
proval of the Oregon Health Sciences University Institutional Animal
Care and Use Committee.
Rat Ucn and CRH were purchased from Bachem (Torrance, CA). For
in vivo studies, LPS (Escherichia coli, serotype 055:B5) was purchased from
Sigma (St. Louis, MO). Recombinant mouse TNFa was purchased from
Roche Molecular Biochemicals (Indianapolis, IN), and recombinant hu-
man IL-1a was a generous gift of Dr. Alvin Stern at Hoffman-LaRoche,
Inc. (Nutley, NJ). For in vitro studies, recombinant mouse TNFa, IL-1a,
and IL-6 were purchased from Endogen, Inc. (Woburn, MA). Corti-
costerone was purchased from Sigma.
In vivo regulation of CRH-R2 mRNA by IL-1a, TNFa,
or corticosterone
Adult female C57Bl/6J mice (8–12 wk) were housed in pairs in
shrouded cages 12 h before the start of the experiment and left overnight
undisturbed to minimize stress, as previously described (19). In separate
experiments, mice were injected ip with either recombinant human
IL-1a (10 mg/mouse), recombinant mouse TNFa [2.5 mg/mouse (1 3 106
U)] or corticosterone (2.5 or 8.3 mg/mouse). Each experiment included
time-matched groups of mice treated with vehicle alone (pyrogen-free
saline for IL-1a and TNFa and pyrogen-free saline containing 11%
ethanol for corticosterone). Animals were killed at the indicated times
after injection (see Results), and hearts were removed from individual
mice and flash frozen separately in liquid nitrogen.
In vivo regulation of CRH-R2 mRNA by LPS in TNFa-R-
deficient mice
Mice homozygous for disruptions in the p55 and p75 forms of TNFa-
receptor (backcrossed four generations onto C57Bl/6J) were inter-
crossed and the genotypes of offspring were confirmed by PCR of tail
DNA (28). Male and female wild-type and TNFa-R (p552/2, p752/2)
mice (7–12 wk) were housed as described above. Mice were killed at 1,
3, 9, or 24 h after ip injection of LPS (50 mg/mouse). Hearts were removed
from individuals and flash frozen separately in liquid nitrogen. This
experiment was performed twice.
In vivo regulation of CRH-R2 mRNA by restraint stress
Adult female C57Bl/6J mice (8–12 wk) were housed as described
above. Unstressed animals (n 5 6 mice) were killed in the morning,
before the initiation of the restraint stress for other groups of mice. All
other mice (n 5 6 mice/group) were restrained for 90 min in ventilated
50 ml polypropylene tubes. Animals were killed immediately, 1.5, 3, or
6 h following the 90-min period of restraint. Hearts were removed and
flash frozen separately in liquid nitrogen.
In vivo corticosterone response to LPS injection
Adult C57Bl/6J male and female mice were pair-housed in shrouded
cages overnight as described above. At 0700 h, mice were injected with
LPS (50 mg/mouse, ip), returned to home cages and killed at 1, 3, 9, or
24 h after injection. Trunk blood was collected in ice-cold EDTA-coated
tubes and plasma was stored at 220 C until hormone assay. Plasma
corticosterone levels were measured using a commercial RIA kit (ICN
Pharmaceuticals, Inc., Costa Mesa, CA).
RNase protection for CRH-R1 and CRH-R2
Quantitation of CRH-R2 mRNA was performed as previously de-
scribed (18). Briefly, total RNA was purified from mouse tissues or
isolated adult mouse ventricular cardiomyocytes using RNA STAT-60
according to manufacturer’s protocol (Tel-Test, Inc., Friendswood, TX).
Mouse CRH-R2 was detected with a 239 nt probe (mCRX-55) spanning
TM3 and TM4 (corresponding to amino acids 204 through 283) (11).
Mouse CRH-R1 was detected with a 169 nt probe spanning TM3 and
TM4 (corresponding to amino acids 234–289). A 216 nt RsaI fragment or
110 nt DdeI fragment of L3 cDNA, encoding a mouse ribosomal protein
(29) was used as a control for equivalent loading of RNA. Under certain
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hybridization conditions, a L3 doublet at ;110 nt is visible. 32P-UTP
probes for CRH-R2, CRH-R1, and mouse L3 were synthesized in vitro
and hybridized to total RNA overnight. Reactions were digested with
RNase A (1 mg/ml) and T1 RNase (600 U/ml) and resolved on a 6%
polyacrylamide gel. Gels were exposed to phosphorimage screens.
Quantitation of CRH-R2 mRNA in heart and isolated ventricular car-
diomyocytes was performed using the IP Lab Gel software package
(Signal Analytics, Vienna, VA). All CRH-R2 band intensities were nor-
malized to L3 band intensities from the same RNA sample.
Isolation of adult mouse ventricular cardiac myocytes
Cardiomyocytes were isolated from hearts of adult wild-type
(C57Bl/6) or Crhr22/2 mice as described (30, 31). Briefly, mice were
injected with heparin (200 U) and anesthetized with a mixture of
ketamine (8 mg/mouse) and xylazine (2 mg/mouse). Hearts were
removed with the aorta intact and connective tissue was removed.
Hearts were mounted onto a modified Langerdorf apparatus and
perfused with a 95% O2/5% CO2 saturated Ca
21 free modified
Tyrode’s solution for approximately 1 h. Hearts were subsequently
perfused with Tyrode’s solution containing 2 mg/ml collagenase type
II (CLS2, Worthington Biochemicals, Freehold, NJ) until the tissue
was soft. Ventricles were removed, teased apart and incubated in
collagenase solution. Cardiomyocytes were allowed to pellet under
gravity for 20 min and the supernantant (nonmyocytes) was aspirated
off. Isolated cells were passed through a 70 mm mesh filter and plated
onto laminin-coated Primaria (Becton Dickinson, Franklin Lakes, NJ)
tissue culture plates in DMEM containing 10% FBS, sodium pyruvate,
nonessential amino acids, holo-transferrin (5 mg/ml), insulin (10 mg/ml),
cytosine-b-d-arabinofuranoside (3 mg/ml), 23 MEM vitamins and
penicillin/streptomycin.
In vitro regulation of CRH-R2 mRNA in adult mouse
ventricular cardiac myocytes
Cardiomyocytes were plated onto laminin-coated 60 mm Primaria
dishes and cultured overnight at 37 C in a humidified 5% CO2 incubated
chamber. In separate experiments, graded doses of Ucn (0.1–100 nm),
cytokines [TNFa (5 or 25 ng/ml), IL-1a (2 or 20 ng/ml), or IL-6 (5 or 25
ng/ml)] or corticosterone (5 mm) were added to the culture medium and
cells were incubated for 9 h. Control wells received culture medium
alone. Cells were lysed in RNA-STAT60 (Tel-Test, Inc., Friendswood,
TX) and RNA was isolated as described above. Experiments were per-
formed three times with duplicate wells assayed in each experiment.
To verify that our model of isolated myocyte cultures is responsive
to cytokines, RT-PCR was used to measure cytokine-stimulated induc-
tion of inducible nitric oxide synthase (iNOS), an enzyme whose gene
expression is regulated by LPS or cytokine exposure in rat and mouse
cardiomyocytes (32, 33). Total RNA was collected from adult mouse
cardiomyocytes following 9 h incubation with media alone or media
containing IL-1a (20 ng/ml). Genomic DNA was removed with DNase
treatment for 3 h at 37 C before reverse transcription at 42 C. A portion
of each sample was processed without the addition of reverse tran-
scriptase to verify the absence of contaminating DNA. PCR amplification
of iNOS cDNA was allowed to progress for 33 cycles (determined in pilot
studies to be in the linear range of amplification for iNOS; 1 min 94 C,
1 min 58 C, 1 min 72 C). RNA from a mouse macrophage cell line (J774.2),
known to express iNOS upon stimulation with LPS was used as a
positive control.
Stimulation of cAMP production in adult mouse ventricular
cardiac myocytes
Cardiomyocytes were plated into laminin coated 24-well Primaria
tissue culture plates and cultured overnight at 37 C (5% CO2). Cells were
washed and incubated in serum-free DMEM for 90 min followed by 30
min incubation in serum-free DMEM containing 1 mm IBMX (Sigma, St.
Louis, MO). Myocytes were stimulated with graded concentrations of
Ucn or CRH (1026 to10212 m) for 25 min in DMEM (1 mm IBMX).
Medium was removed and cells were immediately lysed in extraction
medium (95% EtOH/20 mm HCl) and incubated overnight at 220 C.
cAMP was quantitated using a commercially available cAMP RIA kit
(Biomed Tech, Inc., Stoughton, MA). Experiments were performed twice
with triplicate wells assayed in each experiment.
Harvesting of individual cardiomyocytes and amplification
of CRH receptor mRNAs by nested RT-PCR
Freshly isolated adult mouse ventricular cardiomyocytes in perfusion
medium were individually harvested using a small-bore (6 mm diam-
eter) glass pipette maneuvered into position by a hydraulic microma-
nipulator apparatus (Narishige, Japan). Cardiac myocytes were cap-
tured by applying negative pressure to the pipette and immediately
placed in 15 ml of 13 reverse transcriptase buffer (Life Technologies, Inc.)
containing 1% NP-40 (Sigma). Cells were stored at 280 C until needed.
To remove genomic DNA, samples were treated with DNase overnight
at 37 C. RT was carried out at 42 C using random hexamers (Amersham
Pharmacia Biotech, Piscataway, NJ). A portion of each sample was
processed without the addition of reverse transcriptase to verify the
absence of contaminating DNA. The integrity of the cDNA was tested
using nested primers for the L3 housekeeping gene. The samples, which
were then used in subsequent PCRs, showed an amplified 395-bp band
following the second round. The first round of PCR amplification for
CRH-R1 and CRH-R2 used specific primer pairs that resulted in the
following fragment sizes: CRH-R1, 157 bp; CRH-R2, 190 bp. These re-
actions (1 ml) were used for the second round of amplification, which
used nested primers located internally to those primers used in the first
round of amplification. The size of the products generated with these
internal primer pairs were 60 bp and 68 bp, respectively. All PCR
amplifications were allowed to progress for 45 cycles (1 min 94 C, 1 min
58 C, 2 min 72 C). RNA from HEK 293 cells transfected with cDNAs for
mouse CRH-R1 or CRH-R2b were used as positive controls.
Primers
Nested primers. L3 housekeeping gene first round: sense (59-GATGTCT-
CACAGGAAATTCTCAGC-39), antisense (59-TAATCTCTGTTCGGT-
GATGGTAGC-39); second round sense (59-TGTGGGAATTCTGG-
GATATGTTGAGACCC-39), antisense (59-TTGTCAAGCTTATGAC-
ATCAATCATCTCATCCTGCC-39). CRH-R1 first round: sense (59-ATC-
CTCATGACCAAACTCCG-39), antisense (59-TGAAGACAACCCTG-
GAGACC-39); second round: sense (59-TACAGGAAGGCTGTGAA-
GGC-39), antisense (59-ACATGTAGGTGATGCCCAGG-39). CRH-R2
first round: sense (59-CTACACCTACTGCAACACGACC-39), antisense
(59-TTCGCAGTGTGAGTAGTTGACC-39); second round: sense (59-AC-
CCGGAGCCCTAGTAGAGA-39), antisense (59-TTCCGGGTCGTGTT-
GTACTT-39).
iNOS primers for RT-PCR. Sense (59-GTCAACTGCAAGAGAACG-
GAGAAC-39), antisense (59-GAGCTCCTCCAGAGGGTAGG-39).
Statistical analysis
Data were analyzed using ANOVA grouped on time or dose. Follow
up analyses were performed using Newman-Keuls posthoc test. Dif-
ferences in CRH-R2 mRNA levels between wild-type and TNFa-R
(p552/2, p752/2) mice were examined using pooled RNA for each time
point per genotype. Thus, statistical analysis could not be performed due
to the lack of variance in this experiment. CRH-R2 mRNA expression
was examined in individual wild-type and TNFa-R (p552/2, p752/2)
mice at the 9 h timepoint and analyzed using Student’s t test. Differences
were considered statistically significant when P , 0.05.
Results
TNFa and IL-1a regulate CRH-R2 mRNA in the heart
in vivo
We have previously shown that injection of LPS causes a
time-dependent down-regulation of CRH-R2 mRNA in the
heart (19). We investigated here whether administration of
the inflammatory cytokines, IL-1a and TNFa also modulate
expression of CRH-R2 in heart. Mice were injected with IL-1a
(10 mg) or pyrogen-free saline (vehicle) and killed at various
times (1, 3, 6, 9 h) post injection. IL-1a administration in-
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duced a marked time-dependent decrease in CRH-R2 mRNA
levels in the heart (Fig. 1, A and B) with marked suppression
(12% and 5% of control values) by 6 h and 9 h, respectively,
(P , 0.001). CRH-R2 mRNA levels in the heart also decreased
significantly over time following treatment with TNFa (2.5
mg) (Fig. 2), although the reduction was not as dramatic as
observed following IL-1a treatment. By 9 h post injection,
CRH-R2 mRNA levels in the heart dropped to 50% of control
levels (P , 0.05). Thus, cytokines modulate cardiac CRH
pathways supporting the link between cardiac CRH re-
sponses and immune activation.
While TNFa administration caused a significant reduction in
CRH-R2 mRNA, the effect was not as marked as with IL-1a. To
examine whether the modest influence of TNFa on CRH-R2
regulation corresponded to a dose physiologically relevant to
endogenous TNFa release, we administered LPS (50 mg/
mouse, ip) to wild-type and TNFa receptor double knockout
(p552/2, p752/2) mice (27). Systemic LPS injection caused a
decrease in CRH-R2 mRNA levels in the hearts of wild-type and
TNFa-R (p552/2, p752/2) mice compared with time-matched,
vehicle-injected controls (Fig. 3A). This decrease reached 34% of
controls in wild-type mice by 9 h after injection of endotoxin
and had not yet returned to basal levels by 24 h. However, the
decrease in CRH-R2 mRNA in cardiac tissue of TNFa-R
(p552/2, p752/2) mice at 9 h was less pronounced (65% of
control) compared with wild-type mice (P , 0.001) (Fig. 3B).
These results, and those showing 50% reduction in CRH-R2
mRNA expression following systemic treatment with TNFa
(Fig. 2), indicate that TNFa modestly regulates CRH-R2 mRNA
expression in the heart in vivo in comparison to IL-1a and points
to a partial role for this cytokine in mediating LPS-induced
down-regulation of this receptor.
Corticosterone and restraint stress down-regulate
cardiac CRH-R2
Inflammation and cytokines are potent activators of the HPA
axis (20) resulting in elevated levels of glucocorticoids. In our
studies, LPS treatment (50 mg/mouse, ip) significantly increases
circulating corticosterone levels 1 h post injection (saline control
33.2 6 3.4 vs. LPS treated 618 6 76.8, P , 0.001) that remain
elevated 9 h post injection (saline control 239.2 6 58.1 vs. LPS
treated 518.1 6 72.8, P , 0.01). Thus, we investigated whether
corticosterone has an effect similar to those of LPS and cytokines
on cardiac CRH-R2 expression levels. Mice were injected with
corticosterone (2.5 mg or 8.3 mg) or vehicle (pyrogen-free saline
containing 11% ethanol) and killed 4 or 6 h post injection.
Analysis of heart RNA (n 5 6/group) revealed that cardiac
CRH-R2 mRNA levels declined modestly, reaching ;76% of
vehicle-injected control mice 4 h following injection of either a
low or high dose of corticosterone (P , 0.01) (Table 1). Thus,
FIG. 1. IL-1a dramatically down-regulates CRH-R2 mRNA in mouse
heart in vivo. A, IL-1a (10 mg) or vehicle (saline) was injected ip into
C57Bl/6 mice (n 5 6). CRH-R2 mRNA was quantitated by RNase
protection and normalized to L3 mRNA, a ribosomal gene used to
control for RNA loading. Points represent mean CRH-R2 mRNA lev-
els expressed as percent of time-matched, saline-injected controls 6
SEM. **, P , 0.001 using one-way ANOVA with Newman-Keuls
posthoc analysis in time-matched, vehicle vs. treatment groups. B,
Representative RNase protection autoradiograph of heart RNA (mg)
following ip injection of saline or IL-1a. Unh lane contains RNA from
unhandled animals. CRH-R2 probe protects a 239 nt fragment; L3
probe protects a 110 nt fragment.
FIG. 2. TNFa down-regulates CRH-R2 mRNA in mouse heart in vivo.
TNFa (2.5 mg) or vehicle (saline) was injected ip into C57Bl/6 mice
(n 5 4). CRH-R2 mRNA was quantitated by RNase protection and
normalized to L3 mRNA, a ribosomal gene used to control for RNA
loading. Points represent mean CRH-R2 mRNA levels expressed as
percent of time-matched, saline-injected controls 6 SEM. *, P , 0.05,
using one-way ANOVA with Newman-Keuls posthoc analysis in time-
matched, vehicle vs. treatment groups.
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peripheral CRH-R2 is regulated by glucocorticoids, similar to
central CRH-R1. These results suggest that increased levels of
corticosterone following endotoxin and/or cytokine adminis-
tration could in part, contribute to the down-regulation of
CRH-R2 mRNA in the mouse heart.
It is possible that stress-responsive hormones other than
adrenal glucocorticoids regulate CRH-R2 mRNA in the
heart. To begin to investigate this possibility, we subjected
mice to 90 min restraint stress and compared CRH-R2 mRNA
levels in the hearts of mice immediately, 1.5, 3, or 6 h fol-
lowing restraint to those of unstressed controls. Analysis of
heart RNA (n 5 6/group) shows that CRH-R2 mRNA levels
were reduced (66% of unstressed controls, P , 0.01) in hearts
of mice immediately following the termination of the 90 min
restraint period. CRH-R2 mRNA levels were further lowered
1.5 and 3 h post stress (45% and 36% of controls respectively,
P , 0.01) but begin to recover 6 h post stress (Table 2). Thus,
it appears that glucocorticoids or other hormones induced by
a cognitive stress (restraint) may play a role in mediating the
suppressive effects of endotoxin, TNFa or IL-1a on expres-
sion of CRH-R2 in the mouse heart.
Expression and pharmacology of CRH-R2 in adult mouse
ventricular cardiomyocytes
We have shown previously that AT-1 atrial cardiomyocyte
tumor cells express CRH-R2 and respond to CRH with in-
creased cAMP production (18). However, transformed AT-1
cardiomyocyte responses may differ from those of primary
adult cardiac myocytes; hence we tested the use of adult
mouse cardiomyocytes as a suitable in vitro model system by
examining the expression and pharmacology of CRH-R2.
Cultures of highly enriched primary mouse ventricular car-
diomyocytes express CRH-R2 mRNA at levels similar to
those found in whole mouse heart (Fig. 4A). Furthermore, we
do not find evidence of CRH-R1 expression. Although these
primary cultures are enriched for cardiomyocytes, they are
not completely devoid of nonmyocyte cells (90–95% cardi-
omyocytes); thus, we examined individually isolated cardiac
myocytes for expression of CRH-R1 and CRH-R2. Cardio-
myocytes were readily identified microscopically based on
their characteristic striated, rod-shaped appearance in cul-
ture and were individually harvested using a small bore
glass pipette (Fig. 4B). Using nested RT-PCR, we find that
cardiac myocytes express CRH-R2, but not CRH-R1 (Fig. 4C).
The product amplified with CRH-R2 specific primers was
sequenced and found to be identical to mouse CRH-R2. Stim-
ulation of cultured cardiomyocytes with Ucn or CRH causes
a dose-dependent increase in intracellular cAMP (Fig. 4D).
The EC50 values obtained for Ucn (EC50 5 3.3 6 0.5 3 10
210
m) and CRH (EC50 5 3.4 6 1.1 3 10
28 m) are similar to those
reported previously for cells transfected with CRH-R2b (6).
In addition, cAMP responses were not elevated in cardio-
myocytes collected from Crhr22/2 mice, demonstrating that
CRH/Ucn stimulation of cAMP is dependent on the presence
of CRH-R2. Thus, cultured mouse cardiomyoctyes represent
an appropriate in vitro model system to examine the regu-
lation of CRH-R2 in the heart.
CRH-R2 expression in isolated cardiomyocytes is not
regulated by IL-1a, TNFa, IL-6, or corticosterone
We tested whether cytokines and exogenous corticos-
terone that modulate cardiac CRH-R2 mRNA in vivo directly
regulate CRH-R2 mRNA in vitro. Isolated cardiomyocytes
were treated for 9 h with either TNFa (5 or 25 ng/ml), IL-1a
TABLE 1. In vivo corticosterone treatment significantly down-
regulates CRH-R2 mRNA expression in heart tissue
Corticosterone
(n 5 6/group)
Time after injection
4 h 6 h
2.5 mg 78.8 6 4.4a 110.7 6 5.4
8.3 mg 76.2 6 3.9a 100.8 6 6.3
Data are mean values 6 SEM of CRH-R2 mRNA levels expressed as
a percent of time-matched, vehicle-injected controls.
a P , 0.05 treatment group vs. vehicle-injected controls using
ANOVA.
FIG. 3. Regulation of CRH-R2 mRNA in wild-type and TNFa receptor
double knockout (p552/2, p752/2) mice by endotoxin. A, Endotoxin (50
mg/mouse) or vehicle (saline) was injected ip into wild-type (C57Bl/6)
and TNFa-R (p552/2, p752/2) mice. Mice were killed at indicated
times. CRH-R2 mRNA was quantitated by RNase protection and
normalized to L3 mRNA, a ribosomal gene used to control for RNA
loading. Points represent the CRH-R2 mRNA levels in RNA pooled
from wild-type (n 5 3) or TNFa-R (p552/2, p752/2) mice (n 5 6), and
are expressed as percent of time-matched saline-injected controls.
Statistical analysis was not performed due to the use of pooled RNA
samples. B, RNase protection analysis of individual heart RNA sam-
ples from endotoxin-treated animals at the 9 h time point. The error
bar in wild-type mice is too small to be visible on the graph. **P ,
0.001, difference between wild-type and TNFa-R (p552/2, p752/2)
mice, determined by t test. The experiment was performed twice
yielding similar results.
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(2 or 20 ng/ml) or IL-6 (5 or 25 ng/ml) at doses previously
shown to regulate cardiomyocyte function in vitro (26, 34, 35).
We found that treatment with these cytokines failed to sig-
nificantly alter CRH-R2 mRNA in these cells (Fig. 5). How-
ever, iNOS mRNA expression is significantly increased (2-
fold) from basal levels in our cardiomyocyte cultures
following 9 h incubation with IL-1a (data not shown). These
results suggest that the in vivo effects of TNFa and IL-1a on
CRH-R2 levels in the heart are indirect.
To examine the possible role of direct glucocorticoid mod-
ulation, we treated cardiomyocytes with corticosterone (5
mm). This dose of corticosterone has been shown to regulate
several other genes (e.g. adrenomedullin, atrial natriuretic
peptide, Na-K-ATPase genes) in cardiac myocytes and is
20-fold higher than that shown to down-regulate CRH-R1
mRNA in rat pituitary cells (36). CRH-R2 mRNA levels re-
mained unchanged following incubation with corticosterone
for 9 h (Fig. 5).
CRH-R2 expression in isolated cardiomyoctyes is down-
regulated by Ucn
We tested the effect of Ucn, which recently has been re-
ported to be up-regulated in the periphery by LPS (37).
Treatment of cardiomyocytes in vitro with graded doses of
Ucn (0.1–100 nm) for 9 h significantly decreased the level of
CRH-R2 mRNA (59% of controls incubated with medium
alone, P , 0.05) (Fig. 6). Thus, Ucn is capable of regulating
CRH-R2 expression suggesting that LPS and/or inflamma-
tory cytokines may regulate cardiac CRH-R2 mRNA indi-
rectly by inducing and sustaining Ucn or CRH release into
the heart, which subsequently leads to ligand-induced
down-regulation of CRH-R2.
Discussion
Inflammation is a powerful physiologic stress that affects
a number of organ systems leading to marked changes in
energy metabolism, immune function and cardiovascular
homeostasis (38). Sepsis, a potent inducer of systemic in-
flammation, is characterized by vascular dysfunction and
refractory hypotension, a progressive depression of cardiac
function and reduced organ perfusion (39, 40). Depression of
cardiac function in later stages of sepsis may be due, in part,
to TNFa and IL-1, which have been found to be the primary
cardiodepressive factors in plasma of septic individuals (26).
Although diminished cardiac function occurs following pro-
longed inflammation, early stages of sepsis are marked by
increased cardiac function (40), which may be a compensa-
tory response to hypotension resulting from the effects of
inflammatory mediators on vascular endothelium. Increased
cardiac function early in sepsis is likely to be a vital adap-
tation by the host that enhances survival against pathogens.
Moreover, decreased cardiac function following prolonged
inflammation may result from declining inotropic support
due to changes such as receptor sensitivity and relative avail-
ability of inotropic mediators. Thus, mechanisms that lead to
increased positive inotropic support for the heart may be
particularly important during sepsis and endotoxemia.
Given that Ucn increases cardiac contractility via its actions
on CRH-R2 (17), it is plausible that this pathway may play
a role in maintaining inotropic support for the heart. In
addition, we (19) and others (37) have found that endotoxin
modulates this peptide:receptor system, thereby establishing
an important link between CRH-R2 and inflammation.
Our findings reported here add strength to the model that
CRH-R2 responses are linked to inflammatory stimuli. We
show for the first time that in vivo administration of IL-1a
dramatically down-regulates CRH-R2 mRNA in the mouse
heart. In addition, CRH-R2 mRNA expression is also signif-
icantly reduced following systemic administration of TNFa
in wild-type mice, albeit the effect is less marked compared
with IL-1a. The modest regulation by exogenous TNF ap-
pears to reflect endogenous release, as LPS-induced down-
regulation of cardiac CRH-R2 is partially but not completely
prevented in mice lacking TNFa receptors (p55 and p75
forms) compared with wild-type controls. Thus, TNFa does
not regulate cardiac CRH-R2 expression as profoundly as
IL-1. Modulation is likely complex, requiring the actions of
multiple cytokines on various cell types. For example, TNFa
may be involved in stimulating release of IL-1 from circu-
lating macrophages which in turn influences cardiac
CRH-R2.
We paired our in vivo experiments with in vitro analysis
using primary cultures of isolated adult mouse ventricular
cardiomyocytes to examine direct regulation of CRH-R2 by
cytokines. Surprisingly, low or high levels of TNFa or IL-1a
did not significantly regulate CRH-R2 mRNA in isolated
cardiomyocytes. Moreover, IL-6, which is induced by TNFa
and IL-1a, did not alter CRH-R2 mRNA expression in car-
diomyocytes in vitro. These findings suggest that cytokines
do not act directly on cardiomyocytes to modulate CRH-R2
expression. Cytokine regulation of CRH-R2 expression was
recently shown in a transformed line of rat aortic smooth
muscle cells (41), raising the possibility that modulation of
CRH-R2 may be cell type specific. Thus, our observation
of cytokine modulation in vivo could be due to direct effects
of cytokines on nonmyocyte cells in the heart. Alternatively,
as discussed above, it is plausible that several cytokines act
synergistically or in conjunction with other hormones such
as glucocorticoids to influence cardiac CRH pathways. Cy-
tokines are potent stimulators of the HPA axis (42), and
elevations in circulating glucocorticoids have been shown to
regulate CRH-R1 and CRH-R2 expression in the central ner-
vous system (27, 43–45) and more recently in the periphery
(41, 46). We find that in vivo administration of corticosterone
significantly reduced cardiac CRH-R2 mRNA expression 4 h
post injection. In addition, restraint stress resulted in a pro-
nounced decrease in CRH-R2 mRNA levels. Thus, activation
of the HPA axis may play a role in cytokine or LPS-induced
regulation of CRH-R2 in vivo. However, we find that corti-
TABLE 2. CRH-R2 mRNA expression is significantly reduced
during restraint stress
Restraint stress
(n 5 6/group)
Time after 90 min restraint stress
Immediate 1.5 h 3 h 6 h
66.4 6 6.1a 45.1 6 5.7a 36.3 6 10.0a 56.9 6 3.9a
Data are mean values 6 SEM of CRH-R2 mRNA levels expressed as
a percent of unstressed control mice.
a P , 0.01 stressed group vs. unstressed controls using ANOVA
with Newman-Keuls post-hoc analysis.
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costerone does not alter CRH-R2 mRNA expression in mouse
cardiomyocytes in vitro. These data are consistent with a
recent report that showed LPS-induced down-regulation of
CRH-R2 in rat heart was not completely reversed following
adrenalectomy (41). Taken together, it appears that like cy-
tokines, other mediators present in vivo may be necessary for
glucocorticoid regulation of CRH-R2.
We demonstrate that Ucn, a high affinity agonist for CRH-
R2, is capable of down-regulating CRH-R2 mRNA in pri-
mary cultures of cardiomyocytes in a dose-dependent man-
ner. This is similar to CRH-induced down-regulation of
CRH-R1 mRNA in rat anterior pituitary cells (36, 47) and
Ucn-induced down-regulation of CRH-R2 mRNA in trans-
formed smooth muscle cells (41). Moreover, a recent study
reports modest down-regulation of cardiac CRH-R2 mRNA
expression following a bolus injection of Ucn (46). Ligand-
induced down-regulation has also been documented for a
number of other G protein-coupled receptors (48–50) and
often involves decreased mRNA stability (48, 49, 51). Down-
regulation of CRH-R2 mRNA in cardiomyocytes by Ucn may
have important implications for the control of heart function
during stress and suggests that decreases in cardiac CRH-R2
mRNA during inflammation may be due to prolonged ele-
vation of Ucn or CRH levels within the myocardium. In vivo
administration of Ucn lends further support to this view (46),
although paracrine sources of Ucn likely regulate cardiovas-
cular function which may not be simulated accurately with
bolus iv administration. We (Heldwein, K., and M. Stenzel-
Poore, unpublished) and others (52) have found that Ucn and
CRH mRNA are expressed in mouse heart; however little is
known thus far about the regulation of these cardiac tran-
scripts. Heat shock (42 C, 3 h) has been shown to induce Ucn
mRNA expression in cultured neonatal rat cardiomyocytes,
although in this study the increase was minor (;1.8-fold over
control) and seen 18 h after the cells were returned to 37 C
(53).
Inflammation has been shown to regulate Ucn expression
in rat thymus and spleen in vivo (37). Thymic Ucn mRNA
levels were increased 2-fold following systemic endotoxin
administration and decreased to the same degree in the
spleen. Interestingly, this up-regulation of Ucn mRNA in the
thymus was adrenal dependent, and ACTH or corticosterone
also increased thymic Ucn mRNA. In contrast, Ucn mRNA
levels in the spleen were unaltered by ACTH injection. These
data indicate that splenic Ucn expression may be regulated
directly by endotoxin or inflammatory mediators, whereas
HPA axis activation is more important in regulating Ucn in
the thymus. Because changes in Ucn peptide were not mea-
sured in this study, it is not clear how LPS or HPA axis
activation affects the peripheral production of CRH-like pep-
tides (54). Nevertheless, this study indicates that expression
of Ucn in peripheral tissues may be responsive to stress,
particularly those involving inflammatory signals.
In addition to expression changes in the periphery, Ucn
FIG. 4. CRH-R2 expression and cou-
pling to elevations in cAMP in adult
mouse ventricular cardiac myocytes. A,
RNase protection analysis of CRH re-
ceptor expression in cultures of adult
mouse ventricular cardiomyocytes.
CRH-R2 mRNA is highly expressed in
adult mouse cardiomyocytes and whole
heart, while CRH-R1 mRNA is unde-
tectable. B, Harvesting of individual
cardiomyocytes with a 6 mm-bore glass
pipette; note striated, rod-shaped ap-
pearance characteristic of cardiac myo-
cytes. C, RT-PCR analysis of CRH re-
ceptor expression from four ventricular
cardiomyocytes that were individually
isolated and pooled for RT-PCR.
CRH-R2 (68 bp) is evident following two
rounds of PCR amplification. Lane 1, 50
bp ladder; lane 2, CRH-R2 transfec-
tants (HEK 293 cells) amplified with
CRH-R2 primers (11); lane 3, cardiomy-
ocytes amplified with CRH-R2 primers;
lane 4, CRH-R1 transfectants (HEK
293 cells) amplified with CRH-R1 prim-
ers; lane 5, cardiomyocytes amplified
with CRH-R1 primers; lane 6, cardio-
myocytes PCR amplified with L3 prim-
ers with prior reverse transcriptase
treatment; lane 7, cardiomyocytes PCR
amplified with L3 primers without
prior reverse transcriptase treatment.
D, Ucn and CRH stimulate increases in
cAMP accumulation in adult mouse
ventricular cardiomyocytes from wild-
type mice, but not Crhr22/2 mice.
Points are the mean 6 SEM of triplicate
wells/experiment and representative of
duplicate experiments.
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expression in several regions of the central nervous system
are altered by stimuli that influence cardiovascular function.
For example, Ucn expression in the Edinger-Westphal nu-
cleus of the mouse is increased following restraint stress. This
effect was blocked by prior, chronic glucocorticoid infusion
(55) indicating that glucocorticoids may desensitize or down-
regulate pathways that mediate stress-responsive regulation
of Ucn mRNA in the Edinger-Westphal nucleus. Further-
more, the number of Ucn-containing neurons in the supraop-
tic nucleus (SON) and fibers in the median eminence of the
rat brain is increased by dehydration, again demonstrating
that Ucn may be regulated by physiologic stress (56). Inter-
estingly, neurons in the SON are known to be activated by
several vascular stressors (e.g. changes in blood pressure,
volume, and osmolality) (57–59); thus dehydration, which
increases plasma osmolality, may lead to Ucn induction in
the SON and subsequent modulation of the vascular system.
Based on our findings, we propose a model in which
systemic inflammation induces the peripheral production of
Ucn or CRH, which activate CRH-R2 on cardiac myocytes in
the mouse heart. Following prolonged stimulation, CRH-R2
mRNA is down-regulated. Based on the stimulatory activity
of Ucn and CRH on heart function, we posit that CRH-R2
may represent an inotropic pathway that contributes to an
early hyperdynamic response of the heart in response to
hypotension caused by cytokines during sepsis. The studies
presented here provide the basis for future studies using the
power of genetic mouse models that harbor disruptions in
the immune or CRH systems as a means to further dissect the
interaction between immune mediators and CRH pathways
in the heart. We are currently studying the early cardiac
response to inflammation in Crhr22/2 mice. If Crhr22/2
mice show attenuated cardiac contractility in response to
inflammation, this would lend support to our model, reveal-
ing a critical role for CRH-R2 in the regulation of heart
function during stress. To date, our findings (17) and those
of others (5, 7) indicate that Ucn and/or CRH are members
of a family of neuropeptides (60–62) that affect heart func-
tion. Thus, CRH and Ucn may represent a mode of regulation
of the cardiovascular system distinct from catecholamines,
that complements or fine tunes cardiac responses during
adverse conditions that threaten homeostasis.
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